SRSD107 for people with chronic coronary or peripheral arterial disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2a, randomized, double-blind, placebo-controlled, sequential-cohort trial administers multiple doses of SRSD107 or placebo to adults with chronic coronary and/or peripheral arterial disease on background aspirin. The main aims are to characterize pharmacodynamics, safety, and pharmacokinetics of repeated dosing, with participants randomized within dose cohorts and blinded to treatment assignment. Key eligibility includes age 18–75, BMI 18–35 kg/m2, and documented CAD and/or PAD, while excluding participants with bleeding disorders, severe heart failure, non-ischemic cardiomyopathies, recent substance abuse, prior SRSD107 exposure, or recent investigational drug use. The trial is sponsored by Sirius Therapeutics and conducted at Fuwai Hospital in Beijing with serial monitoring and blood sampling to measure drug levels and PD markers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
* Males or females aged 18 to 75 years, inclusive.
* Body mass index (BMI) between 18.0 and 35.0 kg/m2, inclusive.
* History of chronic coronary and/or peripheral arterial disease

Exclusion Criteria:

* Known bleeding disorder
* Severe heart failure with known left ventricular ejection fraction \<35%, or New York Heart Association (NYHA) class III or IV symptoms.
* Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.
* History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.
* Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.
* Previous use of SRSD107.

Where it's running

• Fuwai Hospital
  Beijing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TAVI and PCI vs SAVR and CABG in low- and intermediate-risk patients with severe aortic stenosis and CAD

  This observational study compares TAVI plus PCI to SAVR plus CABG for patients who have both severe aortic stenosis and coronary artery disease.

  Recruiting Alexandria University · Alexandria, Alexandira · NCT07926022

• Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing

  A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jang XI · NCT07881588

• Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD

  This study tests whether taking resveratrol is safe and can change estrogen-related markers in postmenopausal women with coronary artery disease.

  Recruiting InCor Heart Institute · São Paulo, São Paulo · NCT07865377

• Predicting Plaque Growth Using Blood Flow Stress Markers

  This study tests whether combining blood flow patterns in the heart arteries with how blood-flow–sensitive cells respond can help predict which plaques will grow in people with coronary artery disease.

  Recruiting Queen Mary University of London · London · NCT07864051

• Identifying Coronary Plaque Traits with Photon-counting CT and Multimodality Imaging

  This study tests whether advanced imaging can better identify risky artery plaques in people with stable angina.

  Recruiting Queen Mary University of London · London · NCT07864025

• Health for Hungary: Long-term blood and health data collection to study aging and disease onset

  This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.

  Recruiting at 21 sites Center for Molecular Fingerprinting Research Nonprofit LLC · Balatonfüred and 32 other locations · NCT07743021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.